Results 121 to 130 of about 231,458 (256)

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Rituximab for the treatment of patients with chronic lymphocytic leukemia

Cancer Management and Research, 2010
M Gentile, E Vigna, C Mazzone, E Lucia, AG Recchia, L Morabito2, MG Bisconte, C Gentile, F Morabito1UOC di Ematologia, Azienda Ospedaliera di Cosenza, Italy; 2Servicio de Hematología y Hemoterapia, Hospital Universitario de Canarias, La Laguna,
M Gentile, E Vigna, C Mazzone, et al
doaj  

Kinetic uptake of ^99mTc anti-CD20 IgG-SH in CD20+ or CD20- Tumor determined by planar scintigraphy.

, 2015
Data are expressed as ratio between tumor and normal tissue background (muscle). Significant differences were observed between CD20+ and CD20- tumor/muscle ratio at 2h30 and 12h (p = 0,03) and at 24 h (p = 0,02).
Isabelle Quelven (803908), Hélène Carpenet (803906), Jacques Monteil (803907), Armelle Cuvillier (40496)   +3 more
core   +1 more source

Multi‐Omics Integration Reveals Metabolic Reprogramming and EMT‐Driven Metastasis in Triple‐Negative Breast Cancer

Cancer Science, EarlyView.
Integrated transcriptomic, metabolomic, and spatial proteomic profiling of TNBC tumors identifies a metastatic‐associated molecular landscape characterized by EMT activation, metabolic reprogramming, and tumor microenvironment (TME) remodeling. Multi‐omics integration reveals coordinated alterations in EMT signatures, amino acid metabolism, immune ...
Yuheng Pang, Yuefeng Shang, Wenjing Wang, Tong Liu, Xiaolong Zou   +4 more
wiley   +1 more source

Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody

Clinical and Translational Medicine
Background The blood–brain barrier (BBB) presents a major challenge for the development of monoclonal antibody (mAb)‐based therapies for brain disorders.
Vanessa L. Schumacher, Solen Pichereau, Juliana Bessa, Juergen Bachl, Sylvia Herter, Felix C. Weber, Johannes Auer, Anja Kipar, Michael Winter, Martina Stirn, Michael B. Otteneder, Kevin Brady, Anne Eichinger‐Chapelon, Adrian Roth, Nadine Stokar‐Regenscheit, Nicole Clemann, Shanon Seger, Claudia Senn, Juliane Hönig, Cordula Jany, Elisa Di Lenarda, Alain C. Tissot, Christian Klein, H.‐Christian vonBüdingen, Robert Mader, Mohammed Ullah, Niels Janssen, Eduard Urich   +27 more
doaj   +1 more source

Cure of a CD20-positive peripheral T-cell lymphoma-NOS with CHOPE regimen plus surgery a case report and literature review

Frontiers in Medicine
Peripheral T-cell lymphoma non-specific type (PTCL-NOS) is the most common subtype of mature T-cell tumors, which is clinically characterized by high invasiveness and poor prognosis.
Chenyu Chi, Shuo Wang, Man Xu, Yue Shi, Xuehong Ran   +4 more
doaj   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source

Ofatumumab: a novel monoclonal anti-CD20 antibody

, 2010
Thomas S LinGlaxoSmithKline Oncology R&D, Collegeville, PA, USAAbstract: Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic
Thomas S Lin
core  

Aberrant Expression of Multiple T‐Cell Markers in Primary Cutaneous Follicle Center Lymphoma: A Rare Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Aberrant expression of T‐cell markers in B‐cell lymphomas is rare and can pose diagnostic challenges. We report a case of a 65‐year‐old man presenting with newly developed scalp nodules. Histopathology revealed nodular lymphoid infiltrates composed of large centrocytes and centroblasts.
V. Pfefferle, A. Vogelsberg, M. Maaß, C. M. Schürch, S. Forchhammer   +4 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source